Health TrialsbyHealthPanel

Gastroenteropancreatic Neuroendocrine Neoplasm

2

Review clinical trials related to Gastroenteropancreatic Neuroendocrine Neoplasm. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

211At-MABG in Adults With Advanced Neuroendocrine Cancers

Phase I dose escalation study of 211At-MABG in adults with advanced pheochromocytoma / paraganglioma (PPGL) or other NET-overexpressing cancers (as evidenced by positive MIBG imaging) who are refractory to, lacking, or ineligible for approved treatments. Phase 1 dose-escalation will follow a standard 3+3 design with an expansion cohort at the recommended phase two dose (RP2D).

Participants needed: 16
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: University of PennsylvaniaUpdated: Oct 7, 2026Locations: 1
Eligibility criteria

Adult patients, at least 18 years of age [+11]

Women who are pregnant or breast-feeding will not be eligible for this study. [+5]

Read more
Status: Not yet recruiting

Somatostatin Analogues vs. Observation After Peptide Receptor Radionuclide Therapy (PRRT) in Nonfunctional Neuroendocrine Neoplasms

This is a multicenter, randomized, open-label, phase III study comparing standard of care use of somatostatin analogues (SSAs) to standard of care observation in patients with neuroendocrine neoplasms following treatment with Peptide Receptor Radionuclide Therapy (PRRT) (ethanol-stabilized Lu-177 dotatate).

Participants needed: 240
Trial details
Phase: Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: Washington University School of MedicineUpdated: Sep 25, 2026Locations: 2
Eligibility criteria

Histologically or cytologically confirmed metastatic, unresectable, well- or mod... [+8]

Completed prior treatment with PRRT for non-GI-NET diagnosis (i.e. in need of sa... [+7]

Read more